AEON Biopharma, Inc. current report, 14 February 2023

Vollständiges Dokument

Filing Overview

Priveterra Acquisition Corp. filed a Form 8-K dated February 14, 2023. The filing reports a Regulation FD disclosure concerning AEON Biopharma, Inc. It does not present quarterly or annual financial results.

Business Context and Reporting Period

  • Priveterra Acquisition Corp. was the registrant; AEON Biopharma was the subject of the announcement.
  • On February 14, 2023, AEON announced a key opinion leader webinar scheduled for February 24, 2023, at 11:00 a.m. Eastern Time.
  • The webinar would address past, present, and potential future migraine treatments using botulinum toxin.
  • The filing was furnished under Item 7.01, Regulation FD Disclosure, and the information was not deemed filed for purposes of Section 18 of the Exchange Act.

Financial Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.

Material Changes Versus Prior Period

No comparable-period financial information or material operating changes are disclosed.

Guidance, Outlook, Risks, and Unusual Items

  • The announcement concerns an educational and investor-facing webinar regarding botulinum toxin treatments for migraine.
  • No financial guidance, commercialization forecast, clinical results, regulatory determination, or management forecast is provided in the filing text.
  • The filing states that the Item 7.01 information and Exhibit 99.1 are not incorporated by reference into other filings, regardless of general incorporation language.
  • The registrant identified itself as an emerging growth company.

Investor Verification Items

  1. Verify the webinar content and any statements made by AEON regarding botulinum toxin, migraine treatment, clinical development, or market opportunity.
  2. Review AEON’s separate public filings for financial condition, clinical data, regulatory status, financing needs, and commercialization risks.
  3. Confirm that this 8-K contains no financial statements or operating forecasts and that the announcement was furnished rather than filed for liability purposes under Section 18.
  4. Review the referenced Exhibit 99.1 press release for any additional disclosures not included in the filing text.